The biotech company "http://www.oryzon.com/es/inicio" Oryzon has started this week at Vall d’Hebron a new clinical trial of Phase I with ORY-1001, a new drug developed by international researchers in the last 5 years. According to a press release by the company, the new drug is an inhibitor of LSD1 which has already proved in animals that can trigger programmed cell death (apoptosis) in leukemic stem cells, without affecting healthy hematopoietic progenitors. It can also induce normal blasts maturation. The clinical trial is led by Dr. Francesc Bosch, head of the Hematology Service at the Hospital and the Hematology research group at Vall d’Hebron Institute of Research (VHIR). Dr. Olga Salamero, responsible of the Leukemia Unit and researcher from the same group at VHIR, says that during the first phase, “the drug will be administered in over 30 patients with acute myeloid leukemia and any other effective treatment”.Researchers will study the effects and toxicity of this new drug that will be tested for the first time in humans, until the first semester of 2015. During the following months, more Spanish and British hospitals will recruit patients for the clinical trial.